Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide

The farnesyltransferase inhibitor tipifarnib exhibits modest activity against acute myelogenous leukemia. To build on these results, we examined the effect of combining tipifarnib with other agents. Tipifarnib inhibited signaling downstream of the farnesylated small G protein Rheb and synergisticall...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Karp, Judith E., Flatten, Karen, Feldman, Eric J., Greer, Jacqueline M., Loegering, David A., Ricklis, Rebecca M., Morris, Lawrence E., Ritchie, Ellen, Smith, B. Douglas, Ironside, Valerie, Talbott, Timothy, Roboz, Gail, Le, Son B., Meng, Xue Wei, Schneider, Paula A., Dai, Nga T., Adjei, Alex A., Gore, Steven D., Levis, Mark J., Wright, John J., Garrett-Mayer, Elizabeth, Kaufmann, Scott H.
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2009
Matèries:
Clinical Trials and Observations
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2686135/
https://ncbi.nlm.nih.gov/pubmed/19109557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2008-08-172726
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars